DOCSLIB.ORG

Ataxia Research Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ataxia Research Review Ge neratio ns The Official Publication of the National Ataxia Foundation Volume 35, Number 2 Summer 2007 Ata xia Resea rch Review By Harry Orr, PhD Dr. Harry Orr is a full professor for the Department of Laboratory Medicine and Pathology at the University of Minnesota Medical School. Dr. Orr received a BA degree from Oakland University in Rochester, Michigan. He earned his P hD at Washington University and completed a graduate fellowship at Harvard. He is the Director of the Institute for Human Genetics and holds the Tulloch Chair in Genetics. Dr. Orr is known as the researcher who, along with Dr. Huda Zoghbi, found the first gene for ataxia, now known as SCA1. His research is focused on molecular neurogenetics and he is a published author of more than 120 articles, many on the genetics of ataxia. Dr. Orr was appointed the National Ataxia Foundation’s Research Director on June 14, 2006. The following was presented at the 2007 NAF Annual Membership Meeting in Memphis, Tennessee. I have two major goals in this short talk this that the goal here is a treatment or cure for ataxia. morning. One is as Director of Research for the Of course, it needs to be stated that the founda - National Ataxia Foundation: I want to give you tion of this effort is you, the patients and families an overview of ataxia research from the perspec - with ataxia. tive of the meeting today. Clearly, my colleagues Now just a few specific words about the that are coming up after me, after the break, will different types of research. We start with basic give you a much more detailed perspective of a research. This is where we try to find in the lot of the exciting research that is going on in research laboratory the cause of ataxia. What we ataxia. Besides being the Director of Research are looking for, as researchers, are the cellular and for the National Ataxia Foundation, I also head biochemical pathways that are altered as a result up a lab that does research on ataxia, specifically, of the disease. From this information, still in the SCA1, so I thought I would take a moment research lab, we move towards what we call towards the end of the talk to give you a few preclinical research. This is where we test ideas words about where we stand in terms of SCA1. for therapies and largely we test these in model We view research as the bridge to hope. On systems of the disease and we rely very heavily one side of the bridge, the left hand side, we have on the use of animal models. In my own lab we two major classifications of research starting out rely exclusively on the use of a mouse model of with basic research and moving to pre-clinical the disease that we study. There are two types of research. As we move across the bridge we move into clinical trials, and obviously we all are aware Continued on page 3 Page 2 Generations Summer 2007 Please direct correspondence to: Gen erations Staf f: National Ataxia Foundation Julie Braun ..................................... Financial Director 2600 Fernbrook Lane, Suite 119 Sue Hagen ................................ Outreach Coordinator Minneapolis, MN 55447-4752 Becky Kowalkowski .............. Patient Services Director Phone: (763) 55 3- 0020 Mike Parent ................................... Executive Director FAX: (763) 55 3- 0167 Lori Shogren ................... Special Projects Coordinator Internet: www.ataxia.org Donna Gruetzmacher ..................................... Advisor E-mail: [email protected] Design, Production and Printing .............. Leader Printing Generations is published by the National Ataxia Foundation, Inc., Minneapolis, MN. Copyright 2007 by the National Ataxia Foundation, Inc. All rights reserved. We ask that other publications contact us for permission to reprint any article from Generations . Disclaimer The National Ataxia Foundation does not endorse products, services, or manufacturers. Those that are mentioned in Generations are included only for your information. The NAF assumes no liability what - soever for the use or contents of any product or service mentioned in the newsletter. Table of Conten ts Annual Membership Meeting Articles (cont.) Ataxia Research Review ................................. 1 Stock Talk .................................................. 42 Experimental Therapeutics for New NAF Research Program for FA ............... 45 Friedreich’s Ataxia ......................................... 7 International Ataxia Awareness Day .............. 46 Other Movement Disorders in Shopping on the Web .................................. 47 Patients with Ataxia ..................................... 16 Photographs .......................................... 24-26 Research Summaries Blazing a Trail in Researc h: How Does the Normal Function of 2008 Annual Membership Meeting ............... 27 Ataxin-3 Affect Its Fate in Cells? ................... 32 Characterization of Frataxin’s Articles Function in the Stress Response: NAF Giving Options Abound ............................ 6 Taking Advantage of C. Elgans Model ........... 34 From the Desk of the Executive Director ....... 13 Membership Topics Caregiver’s Corner ....................................... 14 NAF Merchandise ......................................... 33 Taking Care of Yourself: Chapter and Support Group News ................. 36 Good Nutrition is Essential and Easy ............ 15 NAF Chapters and Support Groups ................ 38 Generations Word Find ................................ 20 Ambassador Listing ...................................... 41 American Academy of Neurology Conference a Huge Success ........................ 22 Calendar of Events ....................................... 43 Designate Your Research Dollars ................. 22 Memorials and In Your Honor ........................ 47 Family Fund Raisers .................................... 22 Personal Stories and Poems Thank You Athena! ...................................... 29 Murphy’s Gramma ....................................... 12 Featured Board Member I’m Living with Ataxia: of the NAF: Camille Daglio ........................... 30 the Sneak Thief of Life ................................ 23 A Special Thank You to Dr. Susan Perlman ... 31 My Group .................................................... 39 Attention Government Workers ..................... 32 Summer 2007 Generations Page 3 Ataxia Research Review sporadic ataxias and inherited ataxias. We all Continued from page 1 know that if we have a sporadic ataxia, your children are at no increased risk for developing tests that we do in the lab. One test is what we ataxia. Whereas if you have an inherited form of call a proof of principle and this is where we use ataxia, you have gotten the mutated gene from a strategy where we are basically asking the one or both of your parents and if you have question, if we were able to alter this function, children they are also at risk for inheriting this and typically we are using a strategy that we can mutant gene. In the research arena, we focus only use in the research lab, but if we alter this a lot of our attention on the inherited or the function is it a benefit in the disease model. The genetic forms of ataxia. Often it is hard to second, and perhaps more important type of understand why we focus so much attention in preclinical research, is where we are using an our research on these forms of ataxia and less so approach that we think has the possibility of on the sporadic ataxias which, if anything, are being applied to humans. And so, again does this more frequent than the genetic forms. The approach have a positive affect on the disease in simple answer is that we know from a research our animal model? And if in the result of this side how to go from a mutated gene towards preclinical research things go well, we then move understanding the molecular pathway that is forward to what we call clinical trials and this is altered. That is a much more difficult question to where we actually test these potential therapies or therapeutics in humans. address for the sporadic forms of ataxia. So for the inherited ataxias, the roadmap if you will, the I am sure you have heard the different desig - map for research, is to start with families, find nations for clinical research: phase one, phase the gene, understand the mutation and with that two and phase three. These are the trials that are information begin to elucidate the pathways in overseen by the FDA, the Federal Drug Admin - istration. In phase one, the simple question is, the cell that are altered as a result of this mutant “With this drug, what are its toxic effects?” You gene. have heard previously that every drug comes You are going to hear in subsequent talks, for with side effects and comes with toxic effects. example in Friedreich’s ataxia, we know the We are putting chemical agents into the body mitochondria is a major target, the part of the and we basically need to get a handle on what are cell that produces energy. In other forms of ataxia these toxic effects. The basic question is we want we think the nucleus might be the major target to be assured that the drug is certainly no worse of the mutant gene, the region of the cell that than the disease itself. Once a drug or thera- contains our genetic information and controls peutic passes phase one, it moves to phase two. how that genetic information is expressed. Once This is where we begin to ask the question, we understand these molecular pathways, we can “Does this drug have some potential to be effec - then move to therapeutics. Now the hope is tive to treat the disease that we are interested in?” that as, and I think it is being borne out as the If we pass phase two, we move onto phase three, research is progressing, we understand and get which are the large scale clinical trials where we therapeutics for these genetic forms of ataxia are really trying to hone in on how good is this they will also be effective for the sporadic forms drug for therapy in terms of ataxia. Then, of of ataxia. So although the research is perhaps course, if it passes phase three we have a treat - different between the two types of ataxias the ment that can be prescribed by your physician. outcome, hopefully, will be the same.
Load more

Recommended publications
  • Cramp Fasciculation Syndrome: a Peripheral Nerve Hyperexcitability Disorder Bhojo A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by eCommons@AKU Pakistan Journal of Neurological Sciences (PJNS) Volume 9 | Issue 3 Article 7 7-2014 Cramp fasciculation syndrome: a peripheral nerve hyperexcitability disorder Bhojo A. Khealani Aga Khan University Hospital, Follow this and additional works at: http://ecommons.aku.edu/pjns Part of the Neurology Commons Recommended Citation Khealani, Bhojo A. (2014) "Cramp fasciculation syndrome: a peripheral nerve hyperexcitability disorder," Pakistan Journal of Neurological Sciences (PJNS): Vol. 9: Iss. 3, Article 7. Available at: http://ecommons.aku.edu/pjns/vol9/iss3/7 CASE REPORT CRAMP FASCICULATION SYNDROME: A PERIPHERAL NERVE HYPEREXCITABILITY DISORDER Bhojo A. Khealani Assistant professor, Neurology section, Aga khan University, Karachi Correspondence to: Bhojo A Khealani, Department of Medicine (Neurology), Aga Khan University, Karachi. Email: [email protected] Date of submission: June 28, 2014, Date of revision: August 5, 2014, Date of acceptance:September 1, 2014 ABSTRACT Cramp fasciculation syndrome is mildest among all the peripheral nerve hyperexcitability disorders, which typically presents with cramps, body ache and fasciculations. The diagnosis is based on clinical grounds supported by electrodi- agnostic study. We report a case of young male with two months’ history of body ache, rippling, movements over calves and other body parts, and occasional cramps. His metabolic workup was suggestive of impaired fasting glucose, radio- logic work up (chest X-ray and ultrasound abdomen) was normal, and electrodiagnostic study was significant for fascicu- lation and myokymic discharges. He was started on pregablin and analgesics. To the best of our knowledge this is report first of cramp fasciculation syndrome from Pakistan.
    [Show full text]
  • Huda Y. Zoghbi, MD, Howard Hughes Medical Institute, Jan and Dan Duncan Neurological Research Institute at Texas Children’S Hospital and Baylor College of Medicine
    Investigator Spotlight: Huda Y. Zoghbi, MD, Howard Hughes Medical Institute, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital and Baylor College of Medicine It is hard to believe that the 7th World Rett Syndrome Congress has come and gone with great success! Now with summer upon us, IRSF continues to move the spotlight to the committed scientists who have made the World Congress an impressive, high quality meeting with outstanding presentations and discussions. This month we are honored to focus on Dr. Huda Zoghbi who had co-chaired the Basic Research Symposium at the World Congress along with Dr. Gail Mandel. Together, they had produced an exciting lineup of speakers who were encouraged to present new, unpublished data in an effort to foster new ideas that will help chart the course for Rett syndrome research. Dr. Zoghbi is a Howard Hughes Medical Institute (HHMI) Investigator, the Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and Professor of the Baylor College of Medicine in Houston, TX. She received her medical degree from Meharry Medical College and completed residency training in pediatrics and neurology at Baylor College of Medicine where she encountered her first Rett syndrome patient in 1983. Dr. Zoghbi was inspired to receive additional research training in the area molecular genetics and upon completion she joined the faculty of Baylor College of Medicine. In 1999, Dr. Zoghbi and collaborators including research fellow Ruthie Amir made a major breakthrough for Rett syndrome. They had discovered that mutations in MECP2, the gene encoding methyl-CpG-binding protein 2, causes Rett syndrome.
    [Show full text]
  • UC San Diego UC San Diego Electronic Theses and Dissertations
    UC San Diego UC San Diego Electronic Theses and Dissertations Title Spinocerebellar Ataxia Type 7 is Characterized by Defects in Mitochondrial and Metabolic Function Permalink https://escholarship.org/uc/item/02b7m809 Author Ward, Jacqueline Marie Publication Date 2016 Supplemental Material https://escholarship.org/uc/item/02b7m809#supplemental Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Spinocerebellar Ataxia Type 7 is Characterized by Defects in Mitochondrial and Metabolic Function A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Biomedical Sciences by Jacqueline Marie Ward Committee in charge: Professor Albert La Spada, Chair Professor Eric Bennett Professor Lawrence Goldstein Professor Alysson Muotri Professor Miles Wilkinson 2016 Copyright Jacqueline Marie Ward, 2016 All rights reserved The Dissertation of Jacqueline Marie Ward is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Chair University of California, San Diego 2016 iii DEDICATION This work is dedicated to my grandfather, Dr. Wayne Ward, the kindest person I’ve ever known. His memory inspires me to be a better person daily. iv TABLE OF CONTENTS SIGNATURE PAGE .......................................................................................... iii DEDICATION ..................................................................................................
    [Show full text]
  • Program Book
    PARKINSON’SDISEASE2014 ADVANCING RESEARCH, IMPROVING LIVES PROGRAM MATERIALS Sponsored by: January 6 – 7, 2014 Natcher Conference Center National Institutes of Health Bethesda, MD About our cover: The program cover image is a stylized version of the Parkinson’s Disease Motor-Related Pattern (PDRP), an abnormal pattern of regional brain function observed in MRI studies which shows increased metabolism indicated by red in some brain regions (pallidothalamic, pontine, and motor cortical areas), and decreased metabolism indicated by blue in others (associated lateral premotor and posterior parietal areas). Original image used with permission of David Eidelberg, M.D. For further information see: Hirano et al., Journal of Neuroscience 28 (16): 4201-4209. Welcome Message from Dr. Story C. Landis Welcome to the National Institute of Neurological Disorders and Stroke (NINDS) conference, “Parkinson’s Disease 2014: Advancing Research, Improving Lives.” Remarkable new discoveries and technological advances are rapidly changing the way we study the biological mechanisms of Parkinson’s disease, identify paths to improved treatments, and design effective clinical trials. Elucidating mechanisms and developing and testing effective interventions require a diverse set of approaches and perspectives. The NINDS has organized this conference with the primary goal of seeking consensus on, and prioritizing, research recommendations spanning clinical, translational, and basic Parkinson’s disease research that we support. We have assembled a stellar and dedicated group of session chairs and panelists who have worked collaboratively to identify emerging research opportunities in Parkinson’s research. While we have divided our working groups into three main research areas, we expect each will inform the others over the course of the next two days, and we look forward to both complementary and unique perspectives.
    [Show full text]
  • Cerebellar Ataxia
    CEREBELLAR ATAXIA Dr. Waqar Saeed Ziauddin Medical University, Karachi, Pakistan What is Ataxia? ■ Derived from a Greek word, ‘A’ : not, ‘Taxis’ : orderly Ataxia is defined as an inability to maintain normal posture and smoothness of movement. Types of Ataxia ■ Cerebellar Ataxia ■ Sensory Ataxia ■ Vestibular Ataxia Cerebellar Ataxia Cerebrocerebellum Spinocerebellum Vestibulocerebellum Vermis Planning and Equilibrium balance Posture, limb and initiating and posture eye movements movements Limb position, touch and pressure sensation Limb ataxia, Eye movement dysdiadochokinesia, disorders, Truncal and gait Dysmetria dysarthria nystagmus, VOR, ataxia hypotonia postural and gait. Gait ataxia Types of Cerebellar Ataxia • Vascular Acute Ataxia • Medications and toxins • Infectious etiologies • Atypical Infectious agents • Autoimmune disorders • Primary or metastatic tumors Subacute Ataxia • Paraneoplastic cerebellar degeneration • Alcohol abuse and Vitamin deficiencies • Systemic disorders • Autosomal Dominant Chronic • Autosomal recessive Progressive • X linked ataxias • Mitochondrial • Sporadic neurodegenerative diseases Vascular Ataxia ▪ Benedikt Syndrome It is a rare form of posterior circulation stroke of the brain. A lesion within the tegmentum of the midbrain can produce Benedikt Syndrome. Disease is characterized by ipsilateral third nerve palsy with contralateral hemitremor. Superior cerebellar peduncle and/or red nucleus damage in Benedikt Syndrome can further lead in to contralateral cerebellar hemiataxia. ▪ Wallenberg Syndrome In
    [Show full text]
  • Huda Zoghbi: Taking Genetic Inquiry to the Next Level
    Spectrum | Autism Research News https://www.spectrumnews.org NEWS, PROFILES Huda Zoghbi: Taking genetic inquiry to the next level BY RACHEL ZAMZOW 25 JUNE 2021 Listen to this story: Most mornings, Huda Zoghbi, 67, climbs a glass-encased, curling staircase to reach her lab on the top and 13th floor of the Jan and Dan Duncan Neurological Research Institute in Houston, Texas. The twisting glass tower, which she designed with a team of architects, echoes the double helix of DNA — a structure that has been central to her career-long quest to uncover genes underlying neurological conditions. As the institute’s director — and as a scientist— she is known for going beyond the standard job description. Genetics researchers often cast a wide net and sequence thousands of genes at a time. But in her prolific career, Zoghbi has focused on a handful of genes, methodically building up an understanding of their function one careful step at a time. Thanks to that approach, Zoghbi has made a number of landmark discoveries, including identifying the genetic roots of Rett syndrome, an autism-related condition that primarily affects girls, as well as the genetic mutations that spur spinocerebellar ataxia, a degenerative motor condition. She has authored more than 350 journal articles. Her accomplishments have earned her almost every major biology and neuroscience research award, including the prestigious Breakthrough Prize in 2017 and the Brain Prize in 2020. “She’s clearly the international leader in the field,” said the late Stephen Warren, professor of human genetics at Emory University in Atlanta, Georgia. Zoghbi never set out to lead a large research center, she says — her heart is in the lab.
    [Show full text]
  • Spinocerebellar Ataxia Type 29 Due to Mutations in ITPR1: a Case Series and Review of This Emerging Congenital Ataxia Jessica L
    Zambonin et al. Orphanet Journal of Rare Diseases (2017) 12:121 DOI 10.1186/s13023-017-0672-7 RESEARCH Open Access Spinocerebellar ataxia type 29 due to mutations in ITPR1: a case series and review of this emerging congenital ataxia Jessica L. Zambonin1*, Allison Bellomo2, Hilla Ben-Pazi3, David B. Everman2, Lee M. Frazer2, Michael T. Geraghty4, Amy D. Harper5, Julie R. Jones2, Benjamin Kamien6, Kristin Kernohan1,4, Mary Kay Koenig7, Matthew Lines4, Elizabeth Emma Palmer8,9, Randal Richardson10, Reeval Segel11, Mark Tarnopolsky12, Jason R. Vanstone4, Melissa Gibbons13, Abigail Collins14, Brent L. Fogel15, Care4Rare Canada Consortium, Tracy Dudding-Byth16 and Kym M. Boycott1,4 Abstract Background: Spinocerebellar ataxia type 29 (SCA29) is an autosomal dominant, non-progressive cerebellar ataxia characterized by infantile-onset hypotonia, gross motor delay and cognitive impairment. Affected individuals exhibit cerebellar dysfunction and often have cerebellar atrophy on neuroimaging. Recently, missense mutations in ITPR1 were determined to be responsible. Results: Clinical information on 21 individuals from 15 unrelated families with ITPR1 mutations was retrospectively collected using standardized questionnaires, including 11 previously unreported singletons and 2 new patients from a previously reported family. We describe the genetic, clinical and neuroimaging features of these patients to further characterize the clinical features of this rare condition and assess for any genotype-phenotype correlation for this disorder. Our cohort consisted of 9 males and 12 females, with ages ranging from 28 months to 49 years. Disease course was non-progressive with infantile-onset hypotonia and delays in motor and speech development. Gait ataxia was present in all individuals and 10 (48%) were not ambulating independently between the ages of 3–12 years of age.
    [Show full text]
  • Diagnostic Clues in Multiple System Atrophy
    DO I:10.4274/Tnd.82905 Case Report / Olgu Sunumu Diagnostic Clues in Multiple System Atrophy: A Case Report and Literature Review Multisistem Atrofi Tanısında İpuçları: Bir Olgu Sunumu ve Literatürün Gözden Geçirilmesi Mehmet Yücel, Oğuzhan Öz, Hakan Akgün, Semai Bek, Tayfun Kaşıkçı, İlter Uysal, Yaşar Kütükçü, Zeki Odabaşı Gülhane Military Medical Academy, Ankara, Turkey Sum mary Multiple system atrophy (MSA) is an adult-onset, sporadic, progressive neurodegenerative disease. Based on the consensus criteria, patients with MSA are clinically classified into cerebellar (MSA-C) and parkinsonian (MSA-P) subtypes. In addition to major diagnostic criteria including poor response to levodopa, and presence of pyramidal or cerebellar signs (ataxia) or autonomic failure, certain clinical features or ‘‘red flags’’ may raise the clinical suspicion for MSA. In our case report we present a 67-year-old female patient admitted to our hospital due to inability to walk, with poor response to levodopa therapy, whose neurological examination revealed severe Parkinsonism, ataxia and who fulfilled all criteria for MSA, as rarely seen in clinical practice.(Turkish Journal of Neurology 2013; 19:28-30) Key Words: Multiple system atrophy, autonomic failure, diagnostic criteria Özet Multisistem atrofi (MSA) erişkin dönemde başlayan, ilerleyici, nedeni bilinmeyen sporadik nörodejeneratif bir hastalıktır. MSA kabul görmüş tanı kriterlerine göre klinik olarak serebellar (MSA-C) ve parkinsoniyen (MSA-P) alt tiplerine ayrılmaktadır. Düşük levadopa yanıtı, piramidal, serebellar bulguların (ataksi) ya da otonomik bozukluk olması gibi majör tanı kriterlerininin yanında “red flags” olarak isimlendirilen belirgin klinik bulgular ya da uyarı işaretlerinin olması MSA tanısı için klinik şüpheyi oluşturmalıdır. Olgu sunumunda 67 yaşında yürüyememe şikayeti ile polikliniğimize müracaat eden ve levadopa tedavisine düşük yanıt gösteren ciddi parkinsonizm bulguları ile ataksi bulunan kadın hasta MSA tanı kriterlerini tam olarak karşıladığı ve klinik pratikte nadir görüldüğü için sunduk.
    [Show full text]
  • Nocturnal Leg Cramps: Is There Any Relief?
    Nocturnal leg cramps: is there any relief? Nocturnal leg cramps are common, particularly in older people and in women who are pregnant. The condition is characterised by painful cramps in the legs or feet, that affect sleep quality. Is there an effective treatment? Unfortunately, treatment options are limited, but lifestyle modifications and gentle stretching may have some effect. Pharmacological treatment may be considered for people with frequent, severe leg cramps, however, quinine is no longer recommended. What are nocturnal leg cramps? Factors known to be associated with an increased risk of nocturnal cramping, include:1 A nocturnal leg cramp is a sudden contraction of muscles in the leg or foot during sleep. This painful tightening of the Age over 50 years muscle can last from a few seconds to several minutes. Cramps Pregnancy often cause waking, and although the cramps themselves are Exercise, particularly over-exertion benign, the affected muscle may be painful for some hours Leg positioning, e.g. prolonged sitting with legs afterwards and the consequences of sleep impairment can be crossed, tight bed covers which cause the toes to point considerable. downwards Excessive consumption of alcohol Severe nocturnal cramps are characterised by painful, incapacitating episodes, which last on average for nine Chronic dehydration minutes, and recur intermittently throughout the night.1 Structural disorders, e.g. flat feet or other foot and ankle This can lead to secondary insomnia and impaired day-time malformations functioning. Approximately 20% of people who experience Medicines, e.g. diuretics (especially thiazide and regular nocturnal cramps have symptoms severe enough to potassium-sparing diuretics), some anti-inflammatories affect sleep quality or require medical attention.1 (e.g.
    [Show full text]
  • Limb Dystonia Including Writer's Cramp
    Limb dystonia including writer’s cramp Limb dystonia can occur in primary dystonias or as a complication in neurodegenerative diseases e.g. Huntington’s disease, Wilson’s disease or Parkinson syndromes or other diseases like structural brain damage, peripheral trauma or drug-induced. Any muscle group under voluntary control can be affected, dystonic muscle overactivity can occur during rest, be aggravated by movement, or occur only during voluntary movement (action dystonia). If the dystonia is triggered by a specific task, it is called “task-specific” dystonia and affects mostly the hand. As task-specific dystonia causes most disability and is the greatest therapeutic challenge, this summary will focus mainly on this form of limb dystonia. Exercises with a repetitive movement pattern such as writing, typing or playing musical instruments are predestinated to this type of dystonia (1). Co-contraction of agonist and antagonist muscles lead to abnormal postures and movements sometimes associated with tremor or myoclonic jerks. This leads to disability in occupations with repetitive fine motor tasks. The underlying pathophysiology why some individuals develop such a task-specific dystonia and others not, despite of maybe excessive overuse of the hand remains unclear. Safety and efficacy of botulinum toxin has been well established during decades of use (2). Pathophysiology Numerous studies in task-specific dystonias have shown abnormalities within the basal ganglia and its circuits, decreased inhibition at various levels of the sensorimotor system, abnormal plasticity and impaired sensorimotor processing (3). MRI- based volumetric techniques have shown changes in the basal ganglia, thalamus and gray matter of the sensorimotor cortex (4).
    [Show full text]
  • Molecular Diagnostics of Charcot-Marie-Tooth Disease and Related Peripheral Neuropathies
    17_Lupski 3/30/06 1:47 PM Page 243 NeuroMolecular Medicine Copyright © 2006 Humana Press Inc. All rights of any nature whatsoever reserved. ISSN0895-8696/06/08:243–254/$30.00 doi: 10.1385/NMM:8:1:243 REVIEW ARTICLE Molecular Diagnostics of Charcot-Marie-Tooth Disease and Related Peripheral Neuropathies Kinga Szigeti,1 Eva Nelis,2,3 and James R. Lupski*,1,4 1Departments of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; 2Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium; 3Laboratory of Neurogenetics, Institute Born-Borge, University of Antwerp, Antwerpen, Belgium; and 4Pediatrics, Baylor College of Medicine, and Texas Children Hospital, Houston, TX 77030 Received January 10, 2006; Revised January 13, 2006; Accepted January 13, 2006 Abstract DNAdiagnostics plays an important role in the characterization and management of patients manifesting inherited peripheral neuropathies. We describe the clinical integration of molecular diagnostics with medical history, physical examination, and electrophysiological studies. Mole- cular testing can help establish a secure diagnosis, enable genetic counseling regarding recurrence risk, potentially provide prognostic information, and in the near future may be important for the choice of therapies. doi: 10.1385/NMM:8:1:243 Index Entries:Molecular diagnostics; Charcot-Marie-Tooth disease; CMT; hereditary neuropathy with liability to pressure palsies; HNPP; Dejerine-Sottas neuropathy; DSN; congenital hypomyelinating neuropathy; CHN; CMT1A duplication; HNPP deletion. Introduction genetic testing, one needs to be familiar with the diagnostic tests available, choose the appropriate Molecular genetic diagnosis has become an inte- patients for testing, and utilize the diagnostic tools gral part of the evaluation of patients with hered- in a logical fashion to optimize the use of resources.
    [Show full text]
  • Neurobiology of the Premonitory Urge in Tourette Syndrome: Pathophysiology and Treatment Implications
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by Aston Publications Explorer Author manuscript Author ManuscriptAuthor Manuscript Author J Neuropsychiatry Manuscript Author Clin Neurosci Manuscript Author . Author manuscript; available in PMC 2017 April 28. Published in final edited form as: J Neuropsychiatry Clin Neurosci. 2017 ; 29(2): 95–104. doi:10.1176/appi.neuropsych.16070141. Neurobiology of the premonitory urge in Tourette syndrome: Pathophysiology and treatment implications Andrea E. Cavanna1,2,3,*, Kevin J Black4, Mark Hallett5, and Valerie Voon6,7,8 1Department of Neuropsychiatry Research Group, BSMHFT and University of Birmingham, Birmingham, UK 2School of Life and Health Sciences, Aston University, Birmingham, UK 3University College London and Institute of Neurology, London, UK 4Departments of Psychiatry, Neurology, Radiology, and Anatomy & Neuroscience, Washington University School of Medicine, St. Louis, MO, USA 5Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA 6Department of Psychiatry, University of Cambridge, Cambridge, UK 7Behavioural and Clinical Neurosciences Institute, Cambridge, UK 8Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK Abstract Motor and vocal tics are relatively common motor manifestations identified as the core features of Tourette syndrome. Although traditional descriptions have focused on objective phenomenological
    [Show full text]